Michael Wodkowski1, Marie Hudson1,2,3, Susanna Proudman4,5, Jennifer Walker6, Wendy Stevens7, Mandana Nikpour7,8, Shervin Assassi9, Maureen D Mayes9, Solène Tatibouet3, Mianbo Wang3, Murray Baron1,2,3, Marvin J Fritzler10. 1. a Department of Medicine , McGill University , Montréal , Quebec , Canada . 2. b Division of Rheumatology , Jewish General Hospital , Montréal , Quebec , Canada . 3. c Lady Davis Institute, Jewish General Hospital , Montréal , Quebec , Canada . 4. d Rheumatology Unit, Royal Adelaide Hospital , Adelaide , Australia . 5. e Discipline of Medicine, University of Adelaide , Bedford Park , Australia . 6. f Department of Allergy and Immunology , Flinders Medical Centre , Bedford Park , Australia . 7. g Department of Rheumatology , St. Vincent's Hospital Melbourne , Fitzroy , Victoria , Australia . 8. h Department of Medicine , The University of Melbourne at St. Vincent's Hospital , Melbourne , Victoria , Australia . 9. i Division of Rheumatology and Immunogenetics , University of Texas Health Science Centre at Houston , Houston , TX , USA , and. 10. j Faculty of Medicine, University of Calgary , Calgary , Alberta , Canada.
Abstract
OBJECTIVE: Autoantibodies directed against the two principal antigens of the human exosome complex, PM75 and PM100, are present in systemic sclerosis (SSc) sera and have been associated with myositis and calcinosis. However, there is a paucity of data on the clinical correlates of these autoantibodies separately and in the absence of other SSc-specific antibodies. The aim of this study was to assess the clinical correlates of monospecific anti-PM75 and anti-PM100 in SSc. METHODS: A tri-nation cohort of 1574 SSc subjects was formed, clinical variables were harmonized and sera were tested for anti-PM75 and anti-PM100 antibodies using a line immunoassay. RESULTS: Forty-eight (3.0%) subjects had antibodies against PM75 and 18 (1.1%) against PM100. However, only 16 (1%) had monospecific anti-PM75 antibodies and 11 (0.7%) monospecific anti-PM100 antibodies (i.e. in isolation of each other and other SSc-specific antibodies). Monospecific profiles of each autoantibody included more calcinosis. An increased frequency of myositis was only seen in subjects positive for both anti-PM75 and anti-PM100 antibodies. Lung disease was only associated with anti-PM75 and subjects with anti-PM100 antibodies had better survival compared to other antibody subsets. CONCLUSION: The prevalence of monospecific anti-PM75 and anti-PM100 antibodies in this large SSc cohort was low. Disease features associated with anti-PM/Scl antibodies may depend on particular and possibly multiple antigen specificities. However, due to the small samples, these results need to be interpreted with caution. International collaborations are key to understanding the clinical correlates of uncommon serological profiles in SSc.
OBJECTIVE: Autoantibodies directed against the two principal antigens of the human exosome complex, PM75 and PM100, are present in systemic sclerosis (SSc) sera and have been associated with myositis and calcinosis. However, there is a paucity of data on the clinical correlates of these autoantibodies separately and in the absence of other SSc-specific antibodies. The aim of this study was to assess the clinical correlates of monospecific anti-PM75 and anti-PM100 in SSc. METHODS: A tri-nation cohort of 1574 SSc subjects was formed, clinical variables were harmonized and sera were tested for anti-PM75 and anti-PM100 antibodies using a line immunoassay. RESULTS: Forty-eight (3.0%) subjects had antibodies against PM75 and 18 (1.1%) against PM100. However, only 16 (1%) had monospecific anti-PM75 antibodies and 11 (0.7%) monospecific anti-PM100 antibodies (i.e. in isolation of each other and other SSc-specific antibodies). Monospecific profiles of each autoantibody included more calcinosis. An increased frequency of myositis was only seen in subjects positive for both anti-PM75 and anti-PM100 antibodies. Lung disease was only associated with anti-PM75 and subjects with anti-PM100 antibodies had better survival compared to other antibody subsets. CONCLUSION: The prevalence of monospecific anti-PM75 and anti-PM100 antibodies in this large SSc cohort was low. Disease features associated with anti-PM/Scl antibodies may depend on particular and possibly multiple antigen specificities. However, due to the small samples, these results need to be interpreted with caution. International collaborations are key to understanding the clinical correlates of uncommon serological profiles in SSc.
Authors: S Hoa; M Hudson; Y Troyanov; S Proudman; J Walker; W Stevens; M Nikpour; S Assassi; M D Mayes; M Wang; M Baron; M J Fritzler Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889